World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://www.wjon.org

Original Article

Volume 000, Number 000, June 2024, pages 000-000

Risk Stratification Tools to Aid Decisions on Adjuvant Chemotherapy Usage in Resected Soft Tissue Sarcomas: A Ten-Year Review of an Irish Sarcoma Center Experience

Figures

Figure 1.
Figure 1. Kaplan-Meier curve of overall survival data comparing AJCC high-risk patients versus AJCC low-risk patients, with follow-up duration of 5 years (total n = 60). Censored values (+) indicate the last known follow-up time for those subjects still alive. AJCC: American Joint Committee on Cancer.
Figure 2.
Figure 2. Kaplan-Meier curve of overall survival data comparing Sarculator high-risk patients versus AJCC low-risk patients, with follow-up duration of 5 years (total n = 60). Censored values (+) indicate the last known follow-up time for those subjects still alive. AJCC: American Joint Committee on Cancer.

Tables

Table 1. Clinicopathological Characteristics and Patient Demographics
 
Variable
FNCLCC: French Federation of Cancer Centers.
Median age, years (range)56.5 (18 - 87)
Sex
  Female31 (51.7%)
  Male29 (48.3%)
Tumor size (median, mm), range60 (9 - 240)
  < 50 mm26 (43.3%)
  > 50 mm34 (56.7%)
FNCLCC tumor grade
  15 (8.3%)
  213 (21.7%)
  342 (70%)
Location
  Upper limb21 (35%)
  Lower limb31 (51.7%)
  Trunk8 (13.3%)
Referral to oncology22 (36.7%)
Chemotherapy7
  Neoadjuvant4
  Adjuvant3
Referral to radiation oncology44
Radiotherapy39
  Neoadjuvant23
  Adjuvant16
Median follow-up (months)49 (9 - 135)

 

Table 2. Histological Subtypes and Number of Patients With Tumor
 
Histological subtypesN
Adipocytic tumorsDedifferentiated liposarcoma (n = 4)
Pleomorphic liposarcoma (n = 3)
Myxoid liposarcoma (n = 2)
Fibroblastic/myofibroblastic tumorsMyxofibrosarcoma (n = 4)
Fibromyxoid sarcoma (n = 2)
Inflammatory myofibroblastic tumor (n = 1)
Fibrosarcoma NOS (n = 1)
Vascular tumorsAngiosarcoma (n = 3)
Epithelioid angiosarcoma (n = 1)
Smooth muscle tumorsLeiomyosarcoma (n = 12)
Peripheral nerve sheath tumorsMalignant peripheral nerve sheath tumor (n = 3)
Skeletal muscle tumorsSpindle cell sarcoma (n = 1)
Pericytic (perivascular) tumorsPEComa (n = 1)
Tumors of uncertain differentiationPleomorphic sarcoma, undifferentiated (n = 10)
Synovial sarcoma (n = 5)
Epithelioid sarcoma (n = 3)
Undifferentiated sarcoma (n = 3)
Clear cell sarcoma (n = 1)
Myxoid sarcoma (n = 1)

 

Table 3. Risk Prediction Outcomes
 
Sarculator score (risk assessment)Patients, nDeaths, n (%)5-year OS rate
OS: overall survival; AJCC: American Joint Committee on Cancer.
High risk198 (42.1%)60.20%P value = 0.009
Low risk416 (14.6%)87.10%
AJCC staging (risk assessment)Patients, nDeaths, n (%)5-year OS rate
High risk258 (32%)67.60%P value = 0.083
Low risk356 (17%)86.30%